ClinicalTrials.gg
WithdrawnNCT04064021Updated Oct 12, 2022

Acupuncture Treatment for Improving Alzheimer's Dementia

An interventional study of Acupunture in Cognitive Deficits and Alzheimer Disease, sponsored by N & S Neurology Center, A Medical Group, Inc. Withdrawn. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by N & S Neurology Center, A Medical Group, Inc · Not applicable, Interventional, and Treatment

Why this study was withdrawn
due to covid19 pandemic
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
60 Years to 80 Years
Sex
All
01

Study summary

Evaluate cognitive improvement pre amd post acupuncture treatment in patients with probable alzheimer's dementia as measured by MOCA score and also per form A( measure of patient's personal information). Also caregiver input.

Read the detailed description

Patient's with diagnosis of probable mild to moderate AD will be enrolled in this study. Patient will undergo neurological examination including MOCA. Examiner will also fill out Form A at the time of initial evaluation.

Patient will then undergo series of acupuncture treatments 2 per week for 6 weeks(12 acupuncture treatment). At end of this intervention patients will be reassessed using same testing(MOCA and form A) Data collected will be assessed via statistical analysis to see if there is any statistically significant improvement.

Acupuncture points used in this trial will stay the same for all subjects and throughout the course. The points will be Si Shen Chong, ST36, 37, LV 2,3,6, GB 34, 39, Xia San Huang, LI 11, LI 4.

02

Conditions studied

  • Cognitive Deficits
  • Alzheimer Disease

Keywords

  • Acupunture
03

In context

Cognition Disorders

419 studies on the registry are indexed under Cognition Disorders; 89 are open to participants now.

Browse Cognition Disorders studies →

Lead sponsor

This is the only study on the registry with N & S Neurology Center, A Medical Group, Inc as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild to moderate AD

Exclusion criteria

Exclusion Criteria:

  • Severe AD
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Acupuncture

    Acupuncture 12 sessions over 6 week to be given to pateints

    Procedure: Acupunture

Interventions

  • ProcedureAcupunture

    Patient will receive 12 acupuncture treatments over 6 weeks (2x per week)

06

What researchers measure

Primary outcomes

  1. Improvement on Montreal Cognitive Assessment test of 5 points or more than baseline( total score is out of 30 points)

    Subject will complete 3 MOCA assessment prior to study over 1 week time. Best score of three is used. After study is complete subject will also undergo 3 MOCA assessment over 1 week immediately after study. Again best score is used.

    Time frame: 12 weeks

Secondary outcomes

  1. Improvement of Montreal Cognitive Assessment test by category than raw total score

    performance on various subcategory will also be reviewed to see if one category improves over other category. (Example: Visual-spacial parameters improves over language)

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04064021
Lead sponsor
N & S Neurology Center, A Medical Group, Inc
Responsible party
Sponsor
First posted
Aug 21, 2019
Start date
Jan 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 12, 2022

Study contacts

SANJAY CHAUHAN, M.D.
principal investigator · N & S Neurology Center, A Medical Group, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion